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ABSTRACT 
Objectives: Systemic sclerosis (SSc) and rheumatoid arthritis (RA) are autoimmune 
diseases that share clinical and immunological characteristics. To date, several shared SSc-
RA loci have been identified independently. In this study, we aimed to systematically 
search for new common SSc-RA loci through an inter-disease meta-GWAS strategy. 
Methods: We performed a meta-analysis combining GWAS datasets of SSc and RA. The 
top single-nucleotide polymorphisms (SNPs) were followed-up in independent SSc and RA 
case-control cohorts. This allowed us to increase the sample size to a total of 8,830 SSc 
patients, 16,870 RA patients and 43,393 controls.  
Results: The cross-disease meta-analysis of the GWAS datasets identified several loci with 
nominal association signals (P-value < 5 x 10
-6
), which also showed evidence of 
association in the disease-specific GWAS scan. These loci included several genomic 
regions not previously reported as shared loci, besides risk factors associated with both 
diseases in previous studies. The follow-up of the putatively new SSc-RA loci confirmed 
IRF4 as a shared risk factor for these two diseases (Pcombined = 3.29 x 10
-12
). In addition, the 
analysis of the biological relevance of the known SSc-RA shared loci pointed to the type I 
interferon and the interleukin 12 signaling pathways as the main common aetiopathogenic 
factors. 
Conclusions: Our study have identified a novel shared locus, IRF4, for SSc and RA and 
highlighted the usefulness of cross-disease GWAS meta-analysis in the identification of 
loci with pleiotropic effects.  
 
  
INTRODUCTION 
Autoimmune diseases (ADs) comprise a group of heterogeneous disorders affecting 
around 5-10% of individuals of European origin. Most ADs are complex traits and the 
current knowledge of the aetiopathogenic factors underlying these diseases is still limited. 
(1) Genome-wide association studies (GWASs) and immune-focused fine-mapping studies 
have revolutionized the understanding of the genetic component of complex ADs by the 
identification of thousands of susceptibility loci associated with autoimmunity, that have 
provided an unbiased support for possible pathogenic pathways, including antigen 
presentation, cytokine signaling, and B and T cells differentiation.(2-3) The vast majority 
of these loci are shared risk factors for at least two or more ADs, pointing to a common 
genetic background and shared molecular pathways underlying autoimmune processes. 
These genetic overlapping has been suspected some time ago, given the high rate of co-
occurrence of ADs in patients affected by another immune-mediated disease and the well-
established familial aggregation reported for these immune disorders. (4)  
Systemic sclerosis (SSc) and rheumatoid arthritis (RA) are complex ADs which share 
clinical and immunological features. Both diseases are rheumatic connective tissue 
disorders, more frequent in women than men, characterized by an exacerbated 
inflammatory response, deregulation of innate and adaptive immunity, including 
autoantibodies production, and systemic complications. (5-6) Thank to the establishment of 
great consortiums and international collaborations, the number of confirmed RA 
susceptibility factors have achieved a total of 101 loci associated with the disease at the 
genome-wide significance level. (7) In regard to SSc, GWASs, Immunochip and candidate 
gene studies have clearly identified several genetic regions involved in SSc susceptibility 
(8-10). However, the knowledge of the genetic predisposition to this disease is still 
relatively limited, in part due to its low prevalence, which makes difficult the recruitment of 
large cohorts that allow reaching a high statistical power to effectively detect association 
signals. Interestingly, a considerable proportion of the SSc susceptibility factors constitute 
also RA risk loci, such as STAT4 (MIM 600558), IRF5 (MIM 607218), IRF8 (MIM 
601565), TNFAIP3 (MIM 191163), CD247 (MIM 186780), DNASE1L3 (MIM 602244), 
ATG5 (MIM 604261), BLK (MIM 191305) and PTPN22 (MIM 600716), suggesting shared 
aetiopathogenic pathways for both ADs (7, 10). In addition, although not very common, co-
familiality and co-occurrence between these two rheumatic conditions has been observed, 
with a weighted estimated prevalence around 5% for patients with SSc and RA according to 
Elhai et al. (2013). (11) These observations provide evidence of a genetic overlapping for 
both diseases, thus it is expected that additional shared risk factors remain to be discovered. 
One approach that has been developed for the identification of common genetic loci in a 
cost-effective manner is to perform a combined-phenotype GWAS, that is, to combine 
genome-wide genotype data from two autoimmune diseases regarding them as a single 
phenotype. This strategy has been successfully applied not only in the study of closely 
related phenotypes, such as Crohn disease (CD) and ulcerative colitis (UC), but also to non-
related phenotypes, showing encouraging results.  (12-16) 
Considering all the above, the goal of the present study was to systematically identify 
new pleiotropic risk loci for SSc and RA by applying the combined-phenotype GWAS 
strategy, followed by replication testing in independent case-control datasets in both 
diseases.  
  
METHODS 
Study population 
The stage I of the present study included 6,537 SSc/RA patients and 8,741 healthy 
controls. SSc GWAS panel comprised four case-control sets from Spain, Germany, The 
Netherlands and US (2,716 cases and 5,666 controls) which were obtained from previous 
studies. (8, 15, 17) RA case-control GWA study included two previously published RA 
GWAS cohorts (WTCCC, EIRA) from UK and Sweden (3,821 cases and 3,075 controls). 
(18)  
The replication stage was drawn in independent SSc and RA case-control sets of 
European ancestry. The SSc replication cohort included 6,114 cases and 8,744 controls 
from 8 different countries (Spain, Germany, Italy, UK, The Netherlands, Sweden, Norway 
and US). The healthy controls from UK and US partially overlapped with control sets of 
previously published cohorts (WTCCC and NARAC2). (18) The RA replication cohort 
included 9 case-control collections from North America (US, Canada), Spain, The 
Netherlands, UK, Sweden, France and New Zealand, and comprised a total of 13,049 RA 
cases and 25,908 healthy controls.  Of these, 9,711 cases and 24,253 healthy controls were 
obtained from several previously published studies (BRASS, NARAC1, CANADA, 
Rheumatoid Arthritis Consortium International for Immunochip (RACI)-US, RACI-i2b2, 
CORRONA, Vanderbilt, RACI-UK, RACI-SE-U, RACI-NL, Dutch (AMC, BeSt, LUMC, 
and DREAM), ReAct, and the anti-TNF response to therapy collection (ACR-REF)) (7). 
SSc patients fulfilled the 1980 American College of Rheumatology (ACR) classification 
criteria for this disease or the criteria proposed by LeRoy and Medsger for early-SSc. (19-
20). All RA patients fulfilled the 1987 criteria of the ACR for RA diagnosis (21) or were 
diagnosed as RA by a professional rheumatologist. All individuals enrolled in the present 
study provided written informed consent and approval from the local ethical committees 
was obtained from all the centers that recruited the participating individuals. 
Study design 
Stage I. In the present study, we performed a two-stage study to systematically identify 
shared risk factors for SSc and RA (Figure 1). In the stage I, we performed GWAS analysis 
for each disease separately and a combined-phenotype GWAS analysis. Two different tests 
that have been successfully applied in previous studies were considered for the combined 
analysis (12, 15): 
1)  In order to detect common signals for SSc and RA with same-direction allelic 
effects, the meta-analysis considering both diseases was performed as usual. Those SNPs 
that showed a P-value < 5 x 10
-6
 in the combined-phenotype analysis and nominal 
significance in the association study for each disease (P-value < 0.05) were selected for 
follow-up in the replication stage. 
2) To identify common signals for SSc and RA with opposite-direction allelic effects, 
we flipped the direction of association (1/OR) in the RA dataset for the combined-disease 
meta-analysis. To select SNPs for replication, the same selection criteria stated above was 
followed.  
For both sorts of meta-analysis, we only considered for follow-up those SNPs that had 
not been previously reported as genetic risk factors for SSc and RA, or those that had been 
reported for one of the disease but not reported for the other. We also did not consider 
markers from the extended HLA region on chromosome six. 
Stage II and meta-analysis.  The selected SNPs were followed-up in independent 
replication cohorts recruited for both SSc and RA studies. After replication stage, we 
performed a meta-analysis of the initial GWAS screening stage and replication stage. The 
SNP signals that reached (1) genome-wide significance level (P-value < 5 x 10
-8
) in the 
combined-phenotype meta-analysis (GWAS + Replication stage), and (2) showed , for each 
disease separately, nominally significant associations (P-value < 0.05) in the replication 
step as well as PGWAS+Repl < 5 x 10
-3 
were considered shared risk factors for the two 
analyzed diseases.  
Quality control and genotype imputation of GWAS data 
We applied stringent QC criteria in all the GWAS datasets. Cutoff values for sample call 
rate and SNP call rate was set at 90%.  Markers with allele distributions deviating from 
Hardy-Weinberg equilibrium (HWE) (P-value < 0.001) in controls of any of the 
populations analyzed separately were excluded. Markers with minor allele frequencies 
(MAFs) lower than 1% were also filtered out. The top 5 principal components were 
estimated and individuals deviating more than six standard deviations (SDs) from the 
cluster centroids in the first three principal components were considered outliers. In 
addition, duplicate pairs or highly related individuals among datasets were also removed on 
the basis of pairwise comparisons by using the Genome function in PLINK (Pi-HAT 
threshold of 0.5) (22). After applying QC criteria, we performed whole-genome genotype 
imputation using HapMap CEU and TSI populations as reference panels.  
Follow-up genotyping 
The genotyping of the replication cohorts was performed with either (1) the TaqMan 
SNP genotyping technology in a LightCycler® 480 Real-Time PCR System (Roche 
Applied Science, Mannheim, Germany), or (2) the GWAS  and Immunochip platforms.  
For the SSc study, all cases were genotyped by TaqMan genotyping system using 
TaqMan 5’ allele discrimination predesigned assays from Applied Biosystems. Genotyping 
call rate was > 95% for the three SNPs. The control samples were also genotyped by this 
technology, with the exception of the UK and USA cohorts. For these two control cohorts, 
genotyping data were obtained from previously published genome-wide genotyping 
datasets (WTCCC and NARAC2). (18)  
RA cases from Spain and New Zealand and Spanish controls were genotyped by 
TaqMan technology. Genotyping data for New Zealander healthy controls partially 
overlapped with those from a previous GWAS report (23). For the remaining RA case-
control sets, genotype frequencies and association data for the three replication SNPs were 
obtained from a previously published study (7). Genotype methods of these studies were 
described in detail in (7). For those cohorts that were genotyped with the Illumina 
Immunochip platform, only data for IRF4 rs9328192 were available.       
Data analysis 
 All data were analyzed using PLINK V.1.07 software (22). To test for SNPs 
association, we performed logistic regression analysis in each of the SSc and RA GWAS 
cohorts separately.  The top three PCs were included as covariates to control for any 
potential population stratification effects. The disease-specific meta-analyses were 
performed with inverse-variance weighting under a fixed-effects model. The meta-analysis 
for the combined-phenotype GWAS analysis was performed considering SSc and RA 
datasets as a single phenotype. The replication cohorts were also analyzed by logistic 
regression analysis. The combined analysis of the discovery and replication cohorts was 
carried out using the inverse variance method based on population specific logistic 
regression results. Heterogeneity of the ORs across studies was assessed using Cochran’s Q 
test. Hardy-Weinberg equilibrium was tested for all the validation cohorts genotyped by 
TaqMan technology (HWE P-values < 0.01 were considered to show significant deviation 
from the equilibrium). None of the included control cohorts showed significant deviation 
from HWE for all the genotyped SNPs, with the exception of HNF1A rs10774577. The 
cohorts that failed HWE were excluded for the analysis of this specific SNP. The 
Manhattan plots were obtained with an in-house modification of the R script written by 
Stephen Turner.  
Functional annotations and enrichment analysis 
We performed functional protein association analyses considering all the shared risk 
factors described to date between SSc and RA in the European population. For this purpose, 
we only included firmly associated loci for both diseases, which were selected on the basis 
of the following criteria: (1) loci associated at the genome-wide significance level (P-value 
5 x 10
-8
), (2) those that reached second tier level associations (p-value < 5x10
-5
), or (3) that 
have been replicated in independent studies. In total, 14 well-established SSc-RA loci were 
included (Figure 3).   
Protein-protein interaction (PPI) analysis. PPIs among the 14 SSc-RA loci were 
interrogated using STRING V.10 that provides a critical integration of protein–protein 
interactions, including direct (physical) as well as indirect (functional) associations. (24) 
We used the Homo sapiens STRING database and applied a confidence score of 0,400.  
Molecular pathway enrichment analysis.  We conducted molecular pathway enrichment 
analyses using the Gene Set Enrichment Analysis (GSEA) and DAVID approaches. (25-27) 
These bioinformatics tools evaluate the overlap of a specific gen set with gen sets from the 
MSigDB collections. The statistical significance of the overrepresentation of functional 
annotation terms is calculated on the basis of a hypergeometric testing. Two MSigDB 
collections (Biocarta and Reactome collections) were used in our analysis.  A False 
Discovery Rate (FDR) correction was applied for the results from GSEA-based results, and 
Bonferroni correction was applied for DAVID-based results.  
  
RESULTS 
Discovery analysis. 
In the stage I of this study we conducted a cross-disease meta-analysis using an inverse 
variance-weighted method in order to identify new putatively shared loci between SSc and 
RA. The SSc and RA genome-wide datasets used for discovery comprised 2,716 
cases/5,666 controls and 3,821 cases/3,075 controls, respectively. The overall workflow of 
the study is illustrated in Figure 1. 
The meta-analysis combining both datasets identified several SNPs from seven distinct 
genomic regions showing a P-value < 5 x 10
-6
, as well as a nominal signal of association 
(P-value < 0.05) in the disease-specific analyses (Table 1, Supplementary Table 2). The 
strongest association was found in the well accepted SSc and RA associated locus IRF5 
(Pcombined = 8.44 x 10
-17
; SSc PGWAS = 1.14 x 10
-16
, OR = 1.52; RA PGWAS = 7.86 x 10
-4
, OR 
= 1.20). Three additional SSc-RA known loci, namely PTPN22, ATG5 and BLK, were also 
identified at this stage. The remaining SNPs were located in three different loci: FBN2 and 
HNF1A that had not been previously reported as genetic risk factors for SSc and RA; and 
IRF4, associated with RA in previous studies (Figure 2, Supplementary Table 2). These 
putatively new shared SNPs were selected for follow-up in additional SSc and RA 
replication cohorts. For IRF4, three SNPs met our criteria for being selected for validation 
in the replication step. In this case, we selected the SNP with the lowest P-value. 
Replication Phase and meta-analysis.  
According to the established thresholds (see Material and Methods section for more 
details), we identified one new association signal shared between SSc and RA at IRF4 for 
SNP rs9328192 (Pcombined = 3.29 x 10-
12
). Furthermore, this IRF4 SNP almost reached 
genome-wide significance in the meta-analysis for each disease separately (SSc PGWAS+Repl 
= 2.78 x 10
-7
, OR = 0.90; RA PGWAS+Repl = 1.44 x 10
-6
, OR = 1.08) (Table 1). We also 
observed significant association signals for HNF1A rs10774577 in the SSc analysis (SSc 
PRepl = 0.036, OR = 0.94; SSc PGWAS+Repl = 1.64 x 10
-4
, OR = 0.91), although no evidence of 
association was observed in the RA analysis. The initial signal observed for FBN2 
rs6897611 in the original scan showed no significant associations in the SSc and RA 
replication cohort datasets.  
Genetic connections across the SSc-RA shared loci 
In order to gain insight into the common aetiopathogenic factors that underlie SSc and 
RA, we performed functional protein association analyses considering the 14 shared risk 
factors described to date between these two diseases (For a more detailed description of the 
included loci, see the Methods section).  
PPI analysis across the 14 well-established SSc-RA shared risk factors showed that our 
network was significantly enriched in interactions (P-value < 5 x 10
-10
), which implies that 
the proteins encoded by the SSc-RA risk loci interact with each other more than expected 
by chance (Figure 3). This enrichment in interactions suggests common altered pathways in 
SSc and RA. Therefore, we conducted molecular pathway enrichment analyses using 
GSEA and DAVID. These analyses identified significant overrepresentations of several gen 
sets that were mainly involved in the immune responses, the type I interferon (IFN) 
signaling pathway and the interleukin 12 (IL-12) signaling pathway (Table 2).  
 
  
DISCUSSION  
In the present study we have identified one new non-HLA susceptibility loci shared 
between SSc and RA, namely IRF4, by a combined-phenotype GWAS strategy in large 
case-control cohorts of SSc and RA. This locus, IRF4, was already known to be involved in 
RA susceptibility, but had not been previously associated with SSc.  (7) 
The cross-disease meta-analysis performed with the SSc and RA GWAS datasets 
identified several SNPs from seven different loci that met our stringent selection criteria for 
the replication phase (Pcombined < 5 x 10
-6
; SSc PGWAS < 0.05; RA PGWAS < 0.05). Four of 
them were already SSc and RA known risk factors (PTPN22, ATG5, IRF5 and BLK), thus 
providing support for the effectiveness of this strategy in the identification of shared risk 
loci (10, 28). It is worth mentioning that these loci were detected by the two different tests 
used in the first stage, which were performed in order to detect both same-direction and 
opposite-direction allelic effects. In fact, the new pleiotropic IRF4 SNP identified in this 
study showed opposite effect for SSc and RA (protection and risk effect, respectively). 
Interestingly, the signal of association found in IRF4 almost reached the genome-wide 
significance level in the meta-analysis for each disease separately (Table 1), besides 
reaching a P-value < 5 x 10
-8
 in the combined-phenotype meta-analysis. The associated 
IRF4 SNP (rs9328192) showed modest effect sizes for SSc and RA. However, we were 
able to capture this association in our meta-analysis thank to the large cohort used in this 
study together with the combined-phenotype approach, which allow us to increase the 
statistical power. This highlights the capability of the combined-phenotype approach in the 
identification of shared variants with low penetrance, whose associations might have been 
missed in disease-specific GWASs due to a lack of power.(13) 
Interferon regulatory factor 4 (IRF4) belongs to the IRF family of transcription factors 
and plays a pivotal role in the development and function of several autoimmune-associated 
cells, such as B cells, T regulatory cells (Treg), T helper cells (Th) and plasma cells. (29-
32) Various genetic and functional studies have pointed to IRF4 as a master regulator for 
autoimmunity.(33-34) It has been demonstrated that IRF4 is a crucial factor for the editing 
and L-chain rearrangements of the B cell receptor, and the pre-B cell expansion, which are 
processes directly related with the development of autoimmunity. (35-36)  In addition, 
IRF4 is a critical controller of the T helper 17 cells (Th17) differentiation (32, 37) and the 
production of interleukin (IL) 17 and 21 (33, 38), which are immune system components 
that play a key role in the pathogenesis of SSc and RA. (39-42) 
The results of the present study add another IRF to the list of IRFs associated with SSc 
(IRF4, IRF5, IRF7 and IRF8) and RA (IRF4, IRF5 and IRF8) (7, 10). IRFs are 
transcriptional regulators of type I IFNs and IFN-inducible genes (43). Therefore, these 
findings provide genetic support for the IFN signature described for SSc and RA patients 
(44-45).  Moreover, our pathway enrichment analysis also identified the type I IFN 
signaling pathway as one of the most relevant common pathways between SSc and RA on 
the basis of their common genetic background. Therefore, deregulation of this signaling 
pathway might be a biological process underlying the onset of these two autoimmune 
rheumatic conditions. 
Regarding HNF1A and FBN2 genetic variants, despite the initial suggestive association 
signals found in the first step of the present study, these loci did not showed genome-wide 
significance in our combined-phenotype meta-analysis. Nevertheless, HNF1A showed 
suggestive evidence of association in the meta-analysis performed in SSc alone. Thus, 
further confirmations through independent studies are needed to confirm and establish this 
locus as a true susceptibility factor for SSc. 
In summary, through a cross-disease meta-analysis of GWASs for SSc and RA, we were 
able to identify a new shared locus for SSc and RA, namely IRF4. The present study, 
together with previous reports, reinforces the idea of the common genetic background for 
SSc and RA.  The identification of these pleiotropic autoimmunity loci may point to 
common pathogenic pathways, which ultimately may represent a clinical advantage, thus 
providing support for drug repositioning on the basis of the true understanding of 
pathogenic mechanisms.  
 
  
FIGURES 
 
Figure 1. Overall workflow of the present study. 
 
  
 Figure 2.  Manhattan plot showing the results of the SSc GWAS and RA GWAS panels, 
and the results of the cross-disease meta-GWAS. 
 Figure 3. Protein protein interaction (PPI) network accros the 14 well-established SSc-
RA loci in STRING. The plot shows the ‘confidence’ view. Thicker lines represent stronger 
associations.  
 
 
 
 
 
 
TABLES (excel file) 
Table 1.  Association results of the cross-disease meta-GWAS for three selected SNPs. 
Table 2. Gene sets that showed a significant enrichment P-value (P-value < 0.05) after False Discovery Rate correction in 
GSEA-based analysis or Bonferroni correction in DAVID-based analysis 
Table Supp. 2. List of SNPs with a combined meta-analysis P value lower than 5x10
-6
, SSc P < 0.05 and RA P < 0.05 in the 
discovery phase. 
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